Evidence map›Paper›PMID 38414008›Full record

ArticleLipids in health and disease2024

Pre-operative levels of angiopoietin protein-like 3 (ANGPTL3) in women diagnosed with high-grade serous carcinoma of the ovary.

Emilie Wong Chong, France-Hélène Joncas, Pierre Douville, Dimcho Bachvarov, Caroline Diorio, Frédéric Calon, Ann-Charlotte Bergeron, Jonatan Blais, Shuk On Annie Leung, Nabil Georges Seidah and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lipids in health and disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Emilie Wong ChongFaculty of Medicine, Laval University, Québec, QC, Canada.
France-Hélène JoncasCentre de recherche sur le cancer (CRC) de l'Université Laval, Québec, QC, Canada.
Pierre DouvilleFaculty of Medicine, Laval University, Québec, QC, Canada.
Dimcho BachvarovFaculty of Medicine, Laval University, Québec, QC, Canada.
Caroline DiorioFaculty of Medicine, Laval University, Québec, QC, Canada.
Frédéric CalonFaculty of Pharmacy, Laval University, Québec, QC, Canada.
Ann-Charlotte BergeronFaculty of Medicine, Laval University, Québec, QC, Canada.
Jonatan BlaisFaculty of Medicine, Laval University, Québec, QC, Canada.
Shuk On Annie LeungRéseau de Recherche sur le Cancer, 9 McMahon, Québec, QC, G1R 3S3, Canada.
Nabil Georges SeidahLaboratory of Biochemical Neuroendocrinology, Institut de Recherches Cliniques de Montréal, Montreal, QC, Canada.
Anne GangloffFaculty of Medicine, Laval University, Québec, QC, Canada. anne.gangloff.1@ulaval.ca.
Université Laval · CAQuebec - Clinical Research Organization in Cancer · CAMcGill University Health Centre · CAMontreal Clinical Research Institute · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer cells need constant supplies of lipids to survive and grow. Lipid dependence has been observed in various types of cancer, including high-grade serous ovarian carcinomas (HGSOC), which is a lethal form of gynecological malignancy. ANGPTL3, PCSK9, and Apo CIII are pivotal lipid-modulating factors, and therapeutic antibodies have been developed against each one (Evinacumab, Evolocumab and Volanesorsen, respectively). The roles -if any- of ANGPTL3, PCSK9, and Apo CIII in HGSOC are unclear. Moreover, levels of these lipid-modulating factors have never been reported before in HGSOC. In this study, circulating levels of ANGPTL3, PCSK9, and Apo CIII, along with lipid profiles, are examined to verify whether one or many of these lipid-regulating factors are associated with HGSOC. Methods ELISA kits were used to measure ANGPTL3, PCSK9 and Apo CIII levels in plasma samples from 31 women with HGSOC and 40 women with benign ovarian lesions (BOL) before treatment and surgery. A Roche Modular analytical platform measured lipid panels, Apo B and Lp(a) levels.Results ANGPTL3 levels were higher in women with HGSOC (84 ng/mL, SD: 29 ng/mL, n = 31) than in women with BOL (67 ng/mL, SD: 31 ng/mL, n = 40; HGSOC vs. BOL P = 0.019). Associations between the lipid panel and ANGPTL3, and the inverse relationship between HDL-cholesterol and triglycerides, were present in women with BOL but not with HGSOC. PCSK9 and Apo CIII were not associated with HGSOC.Conclusions In this cohort of 71 women, ANGPTL3 levels were increased in HGSOC patients. The presence of HGSOC disrupted the classic inverse relationship between HDL and triglycerides, as well as the association between the lipid panel and ANGPTL3. These associations were only maintained in cancer-free women. Given the availability of Evinacumab, a therapeutic antibody against ANGPTL3, the current finding prompts an assessment of whether ANGPTL3 inhibition has therapeutic potential in HGSOC.

Indexed as

CarcinomaOvarian CystsOvarian NeoplasmsAngiopoietin-Like Protein 3Angiopoietin-like ProteinsAngiopoietinsFemaleHumansProprotein Convertase 9TriglyceridesAngiopoietin-Like Protein 3Angiopoietin-like ProteinsAngiopoietinsANGPTL3 protein, humanPCSK9 protein, humanProprotein Convertase 9TriglyceridesANGPTL3Apo CIIIEvinacumabHigh-grade serous ovarian cancerLipid profileLp(a)PCSK9

Identifiers

PMID38414008
PMCPMC10898078
OpenAlexW4392195225

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.